Webinar

Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All

Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of:  Efficiencies in donor selection to reduce uncertainties about HLA matching and improve allogeneic cell therapy outcomes  HLA complexity in cell source selection …

Webinar

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of cord blood…

Webinar

Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out

View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…

Webinar

Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies

Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for allogeneic therapies…